NVNO enVVeno Medical Corp

Price (delayed)

$10.75

Market cap

$7.18M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$31.35

Enterprise value

$5.18M

?
Relative Growth: Rel. Growth: 12
Relative Strength: Rel. Strength: 8
Relative Valuation: Rel. Valuation: N/A
Relative Profitability: Rel. Profitability: 9

Hancock Jaffe Laboratories specializes in developing and manufacturing bioprosthetic (tissue-based) medical devices to establish improved standards of care for treating cardiac and vascular diseases. HJLI currently has two lead product ...

Highlights
NVNO's debt is down by 38% YoY and by 14% from the previous quarter
The EPS has grown by 24% year-on-year and by 5% since the previous quarter
NVNO's quick ratio has shrunk by 50% YoY and by 13% QoQ
The equity has declined by 38% year-on-year and by 12% since the previous quarter

Key stats

What are the main financial stats of NVNO

NVNO stock price

How has the enVVeno Medical stock price performed over time
Intraday
0.38%
1 week
-3.15%
1 month
0.66%
1 year
-91.65%
YTD
-4.27%
QTD
6.12%

Financial performance

How have enVVeno Medical's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$20.01M
Net income
-$18.82M
Gross margin
N/A
Net margin
N/A
enVVeno Medical's operating income has increased by 14% YoY and by 4.3% QoQ
enVVeno Medical's net income has increased by 12% YoY and by 3.4% from the previous quarter

Price vs fundamentals

How does NVNO's price correlate with its fundamentals

Growth

What is enVVeno Medical's growth rate over time

Valuation

What is enVVeno Medical stock price valuation
P/E
N/A
P/B
0.3
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has grown by 24% year-on-year and by 5% since the previous quarter
The price to book (P/B) is 75% lower than the 5-year quarterly average of 1.2 and 63% lower than the last 4 quarters average of 0.8
The equity has declined by 38% year-on-year and by 12% since the previous quarter

Efficiency

How efficient is enVVeno Medical business performance
NVNO's ROE is down by 29% year-on-year and by 9% since the previous quarter
The company's return on assets fell by 25% YoY and by 8% QoQ
The ROIC has contracted by 21% YoY and by 10% from the previous quarter

Dividends

What is NVNO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for NVNO.

Financial health

How did enVVeno Medical financials performed over time
NVNO's quick ratio has shrunk by 50% YoY and by 13% QoQ
enVVeno Medical's current ratio has decreased by 50% YoY and by 12% from the previous quarter
NVNO's debt is 97% less than its equity
NVNO's debt is down by 38% YoY and by 14% from the previous quarter
The equity has declined by 38% year-on-year and by 12% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.